<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517357</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-II-201</org_study_id>
    <nct_id>NCT04517357</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients</brief_title>
  <official_title>A Phase 2 Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in the Treatment of Relapsed Ovarian Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label, 2-arm Phase 2 study to evaluate the efficacy&#xD;
      and safety of Fluzoparib with Apatinib versus Fluzoparib alone, as treatment, in relapsed&#xD;
      ovarian cancer patients. The study contains a Safety Lead-in Phase in which the safety and&#xD;
      tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 2 portion of the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Safety Lead-in) dose limited toxicity (DLT) of Fluzoparib+Apatinib in the first cycle</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Safety Lead-in) Recommended Phase II Dose (RP2D) of Fluzoparib+Apatinib</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Phase 2) Objective response rate（ORR） in relapsed ovarian cancer patients</measure>
    <time_frame>Assessed up to a maximum of 20 months</time_frame>
    <description>Defined as Objective response rate per RECIST 1.1 criteria according to Investigator's assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Exploratory research) Objective response rate（ORR） in relapsed ovarian cancer patients</measure>
    <time_frame>Assessed up to a maximum of 20 months</time_frame>
    <description>Defined as Objective response rate per RECIST 1.1 criteria according to Investigator's assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs+SAEs</measure>
    <time_frame>from the first drug administration to within 30 days for the last treatment dose</time_frame>
    <description>Adverse Events and Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 20 months</time_frame>
    <description>Defined as Progression free survival per RECIST 1.1 criteria according to Investigator's assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 20 months</time_frame>
    <description>Complete response + Partial response + Stable disease (CR+PR+SD) based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>up to 20 months</time_frame>
    <description>Time from documentation of tumor response to disease progression assessed among patients who had an objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate by RECIST 1.1 criteria</measure>
    <time_frame>up to 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate by GCIG CA125</measure>
    <time_frame>up to 20 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Relapsed Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Safety Lead-in or Parallel， Fluzoparib+Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Fluzoparib-Apatinib combination until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzoparib monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive Fluzoparib monotherapy until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploratory cohort: Fluzoparib+Apatinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants who has previously received PARP inhibitor, will receive Fluzoparib-Apatinib combination until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib+Apatinib</intervention_name>
    <description>Fluzoparib-Apatinib combination</description>
    <arm_group_label>Safety Lead-in or Parallel， Fluzoparib+Apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>Fluzoparib monotherapy</description>
    <arm_group_label>Fluzoparib monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib+Apatinib</intervention_name>
    <description>Fluzoparib-Apatinib combination</description>
    <arm_group_label>Exploratory cohort: Fluzoparib+Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically diagnosed high-grade serous or endometrioid recurrent ovarian,fallopian&#xD;
             tube,or peritoneal cancer.&#xD;
&#xD;
          2. Patients must have received at least 2 previous platinum-containing regimens.&#xD;
&#xD;
          3. At least one target lesion.&#xD;
&#xD;
          4. ECOG performance status 0-1.&#xD;
&#xD;
          5. Adequate bone marrow, kidney and liver function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor or Apatinib.For&#xD;
             exploratory cohort ，patients who received PARP inhibitor are eligible;&#xD;
&#xD;
          2. Prior malignancy unless curatively treated and disease-free for &gt; 5 years prior to&#xD;
             study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the&#xD;
             cervix allowed;&#xD;
&#xD;
          3. Radiation or anti-hormonal therapy or anticancer therapy within 14 days before first&#xD;
             administration;&#xD;
&#xD;
          4. Known to be human immunodeficiency virus positive;&#xD;
&#xD;
          5. Known active hepatitis C virus, or known active hepatitis B virus;&#xD;
&#xD;
          6. Untreated and/or uncontrolled brain metastases;&#xD;
&#xD;
          7. Patients with clinical symptoms of cancer ascites, pleural effusion, who need to&#xD;
             drainage, or who have undergone ascites drainage within 3 months prior to the first&#xD;
             administration;&#xD;
&#xD;
          8. Pregnant or breast-feeding women.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Quanren Wang</last_name>
    <phone>+86 18036618570</phone>
    <email>quanren.wang@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li bo</last_name>
    <phone>+86 13124759639</phone>
    <email>bo.li@hengrui.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianqing Zhu</last_name>
      <phone>0571-88122222</phone>
      <email>zjq-hz@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

